Abstract
2/2020
vol. 7
Guidelines/recommendations
Biological therapy of asthma – position statement of Polish Allergology Society (PTA) and Polish Society of Lung Diseases (PTChP)
- Katedra i Klinika Chorób Wewnętrznych, Alergologii i Immunologii Klinicznej, Śląski Uniwersytet Medyczny w Katowicach, Polska
- Klinika Chorób Wewnętrznych, Astmy i Alergii, Uniwersytet Medyczny w Łodzi, Polska
- II Katedra Chorób Wewnętrznych im. prof. A. Szczeklika, Uniwersytet Jagielloński Collegium Medicum w Krakowie, Polska
- II Klinika Chorób Płuc, Instytut Gruźlicy i Chorób Płuc w Warszawie, Polska
- Klinika Alergologii i Chorób Wewnętrznych, Uniwersytet Medyczny w Białymstoku, Polska
- Klinika Pneumonologii i Alergologii Wieku Dziecięcego, Warszawski Uniwersytet Medyczny, Polska
Alergologia Polska – Polish Journal of Allergology 2020; 7, 2: 64–80
Online publish date: 2020/06/24
Biological therapy is the breakthrough in the management of spectrum of various diseases. It also concerns asthma therapy. The data regarding the role of biologics in the treatment strategy of severe asthma are presented. The overview on how mediators of type 2 inflammation drives the pathology of the disease is given. It justifies the biological treatment options approved. The development of treatment strategy targeting non-type 2 inflammation is also highlighted. The data regarding the risk and safety of biologics are discussed. Document includes the featured rules of the classification of patients with severe asthma to this reliable and efficient therapy. The outlook how to perceive the safety of biologics in the time of COVID-19 epidemic is also given.
Keywords
severe asthma, immunopathology, biologics, efficacy, safety
Coverage in
Integrated with
